Investor optimism surges as LakeShore Biopharma reaffirms FY2025 guidance
LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) shares experienced a significant surge following the company’s announcement that it would maintain its fiscal year 2025 (FY2025) guidance unchanged. This reaffirmed outlook has reinvigorated investor confidence, leading to a marked increase in stock value by approximately 7.9%, closing at $3.57. Despite enduring a challenging year, during which shares […]